ROCHESTER, N.Y., July 20, 2006 (PRIMEZONE) -- TGC Ventures International (Pink Sheets:TGVI) announced that Dr. George Grant, M.Sc., Ed.D, C.Chem. has been added to the board of directors. Dr. Grant is a renowned multi talented scientist who pioneered the research on Beta Endorphins in the early eighties. He possesses seven University Degrees, Co-authored 7 best selling books and has lectured to several Fortune 500 companies.
His published articles through the years have drawn thousands of testimonials helping people prevent and reverse many diseases through proper life style and Natural Remedies.
Dr. George Grant, known as "Canada's Wellness Guru," will undoubtedly bring to TGC Ventures Int. a wealth of knowledge and professional business contacts, greatly strengthening TGC Ventures International Management structure.
About TGC Ventures International Inc.
TGC Ventures International Inc. is a medically-related holding company that is targeting the burgeoning multi-trillion dollar Health Care Services and Medical Devices & Supplies Industry. Value proposition resides in both its knowledge infrastructure and in the host of benefits associated with being a United States publicly listed corporation.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this release that are forward-looking statements are based on current expectations and assumptions that are subject to known and unknown risks, uncertainties, or other factors which may cause actual results, performance, or achievements of the company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Actual results could differ materially because of factors such as the effect of general economic and market conditions, entry into markets with vigorous competition, market acceptance of new products and services, continued acceptance of existing products and services, technological shifts, and delays in product development and related product release schedules, any of which may cause revenues and income to fall short of anticipated levels. All information in this release is as of the date of this release. The company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.